KalVista initiates KONFIDENT-KID trial for on-demand treatment of hereditary angioedema attacks with sebetralstat in children aged 2 to 11
KalVista Pharmaceuticals, Inc, today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged 2 to 11 years across seven countries in North America, Europe and Asia. KONFIDENT-KID will collect safety, pharmacokinetic, and efficacy data for each patient for up to one year and will feature a proprietary pediatric oral disintegrating tablet (ODT) formulation of sebetralstat.
Ben Palleiko, Chief Executive Officer of KalVista, said: “We are pleased to announce that the KONFIDENT-KID trial has started earlier than previously anticipated. This timeline reflects the high level of excitement among physicians, caregivers, and our patient advocacy partners regarding the potential of sebetralstat to treat children with HAE. Currently, the only approved on-demand treatment for this population is administered intravenously, making this a critical area of unmet need for people living with HAE.”
If approved, sebetralstat would be the first oral on-demand therapy in pediatric patients aged 2 – 11 years, and only the second FDA-approved on-demand therapy of any type in this population.
(Source: KalVista)
